Recently, the effect of various therapies has been described in a retrospective analysis in children and young adults, showing more objective responses with the Receptor Tyrosine Kinase (RTK) inhibitor sunitinib for MiT-RCC in comparison with sorafenib or mTOR inhibitors (temsirolimus or everolimus) [86]. This evidence concerns the gene NTRK1 and renal cell carcinoma.